ArticleBreast cancer research : BCR2019

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.

Hitisha K Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.